Autologous Fibroblast Therapy
Cultured from patient's own fibroblasts | Direct collagen production
About This Treatment
Autologous fibroblast therapy cultures fibroblasts harvested from patient's skin, then re-injects into skin. Fibroblasts are primary collagen producers, so injecting numerous young autologous fibroblasts enables direct, sustained collagen production.
Unlike traditional growth factor therapy, live cell injection means long-term post-transplant collagen production. Requires 2-4 weeks from harvest to culture to transplant, but harvested cells enable multiple treatments. Autologous cells mean zero rejection, completely safe established therapy.
Mechanism of Action
Cultured and expanded young autologous fibroblasts are injected. Post-transplant, these cells survive and continue native biologic function (collagen I, III synthesis). Simultaneously exert intercellular paracrine effects promoting new fibroblast migration. Sustained collagen production over 3-6 months post-transplant restores skin elasticity and thickness.
Indications
Expected Results
Post-autologous fibroblast injection, collagen production increases at 3-6 months. Deep wrinkles significantly reduce, volume restored. Effects persist 1-2 years post-transplant. Extremely high patient satisfaction.
Clinical Evidence
Risks & Side Effects
Minimal skin biopsy scarring risk. Culture contamination risk. Post-transplant infection risk minimal (autologous). Rarely, transplant site swelling, induration.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition